NCCN releases updates to kidney cancer guidelines

The National Comprehensive Cancer Network (NCCN) has announced that its guidelines on kidney cancer have been updated as a result of new therapeutic options available for advanced kidney cancer. The guidelines panel significantly restructured the treatment recommendations for advanced kidney cancer by delineating treatment by histology and adding treatment options for first- and second-line therapy.

Two kinase inhibitors, sorafenib (Nexavar) and sunitinib (Sutent), were recently approved by FDA and incorporated into the guidelines.

“NCCN guidelines highlight the cutting-edge developments in treatment and are an essential tool for physicians, allied health professionals, patients, and public and private payers,” said William T. McGivney, PhD, CEO of the NCCN.

For a detailed listing of the updates, visit www.nccn.org.